Net Margin: pluri-biotech.com (PLUR)

Symbol and logo of brand Pluri Inc. (PLUR)

The growth of Pluri Inc. (PLUR) is driven by the validation of the PLX 3D platform and partnerships within the bio-industry. The GURU.Markets system provides the sales margin value, where -1943.90 reflects the baseline level of the metric. Its status as an innovator in cell therapy confirms the brand's scientific authority. The seamless supply of bio-components is ensured through diversified logistics routes and warehouse reserves.

Pluri (PLUR) Return on Sales by Net Profit: for the period 04/28/2023 - 11/19/2026

Financial and market metric breakdowns for Pluristem Therapeutics (PLUR)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Initial company analysis:Pluri Inc.
Manufactured product of Pluri

Pluri Inc. is developing a high-tech cell therapy sector that requires colossal capital expenditures. This net profit margin reflects the portion of net income in every dollar of revenue, demonstrating the efficiency of the operating model. Amid liquidity shortages and laboratory costs, this metric reveals a critical depletion of cash reserves. The downward trend of the indicator signals increasing financial vulnerability for the business, rendering the asset high-risk for long-term investment.